TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS National Framework for Transition Products (Nintedanib and Dalbavancin)

No classification published
Location not published
Official notice
Published value
£115,756,000
Submission deadline 28 Jan 2026, 13:00 GMT
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS National Framework for Transition Products (Nintedanib and Dalbavancin)". Published status: complete. Published value: £115,756,000. 1 published lot. Recorded submission deadline: 28 Jan 2026, 13:00 GMT. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
Closed
28 Jan 2026, 13:00 GMT
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)£115,756,000
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
22.8Bids / Report
7.7% of reports have one bid
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable value
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
Supplier NameHistoric AwardsAttributable GBP Value
Anna Freud1 win£5,862,540
Anglia Ruskin University1 win£4,809,159
NHS Shared Business Services Limited1 win£4,393,727
Pearson Professional Assessments Limited1 win£4,374,320
Timewise Foundation CIC1 win£166,667
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published24 Apr 2026, 09:59 BST
Last source update24 Apr 2026, 09:59 BST
Recurring procurementNot published
ClassificationNot published
Delivery areaLocation not published
OCIDocds-h6vhtk-05d361
What is being bought
Project title: NHS National Framework for Transition Products (Nintedanib and Dalbavancin) commencing 1st May 2026 Offer reference number: CM/TNS/25/5736 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/25/5736 Nintedanib and Dalbavancin Lot 1 DLN/DNW: 01/05/2026 to 30/09/2027 (17 months) Lot 2 DLS/DNE: 01/05/2026 to 31/05/2027 (13 months) Lot 3 DCE/DSW: 01/05/2026 to 31/01/2027 (9 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
What changed
From the official release history
  1. Official notice release published
    24 Apr 2026, 09:59 BST
  2. tender value changed
    25 Feb 2026, 13:10 GMT
  3. Status changed to complete
    25 Feb 2026, 13:10 GMT
  4. Official notice release published
    25 Feb 2026, 13:10 GMT
  5. Submission deadline changed to published date
    25 Feb 2026, 13:10 GMT
  6. Published value updated to £115,756,000
    18 Dec 2025, 15:49 GMT
  7. Status changed to active
    18 Dec 2025, 15:49 GMT
  8. Official notice release published
    18 Dec 2025, 15:49 GMT
  9. Submission deadline changed to 28 Jan 2026, 13:00 GMT
    18 Dec 2025, 15:49 GMT
  10. Published value updated to £88,500,000
    24 Oct 2025, 12:45 BST
  11. Status changed to planning
    24 Oct 2025, 12:45 BST
  12. Official notice release published
    24 Oct 2025, 12:45 BST
  13. Buyer information updated
    24 Oct 2025, 12:45 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    24 Apr 2026, 09:59 BST
  2. Submission deadline
    28 Jan 2026, 13:00 GMT
  3. Award active
    Not published · Not published
  4. Contract active
    Signed 27 Mar 2026, 00:00 GMT · £14,758,000
Commercial outcome and competition
Awards
Accord UK Ltd, CELIX PHARMA LTd, DR REDDY'S LABORATORIES (UK) LIMITED, MILPHARM LIMITED, REIG JOFRE UK LIMITED, Zentiva Pharma UK Ltd
Not published · Not published · active
Contracts
Lot 1 - CM/TNS/25/5736 Nintedanib and Dalbavancin
£14,758,000 · signed 27 Mar 2026, 00:00 GMT · active
Contract period: 1 May 2026, 00:00 BST — 30 Sept 2027, 23:59 BST
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-PPON-PDPT-3135-BWWY
View buyer profile
Documents (1)
Official links; attachments are not copied

  • Not published

    tender
    conflictOfInterest
Related procedures (0)
No data
No related procedures published